FSCN1 and carcinoid tumor: showed that FSCN1 immunoreactivity was detected in 5% of typical carcinoids, 35% of atypical carcinoids, 83% of large-cell neuroendocrine carcinomas, and 100% of small-cell lung carcinomas, even though they are all lung tumors.